Media about us

02 December 2015

Pocket or Flap Delivery of Corneal Inlays: Does it Really Matter?

Arthur B. Cummings, MB ChB, FCS(SA), MMed(Ophth), FRCS(Edin) / CRSToday Europe

With the emergence of corneal inlays for the correction of presbyopia, there has been debate on how to implant these devices into the cornea. Of the four inlays on the market, the manufacturers of three of them recommend implanting intrastromally—in a corneal pocket—and one is designed for implantation under a flap.

26 November 2015

Epigenetics Drugs and Diagnostic Technologies Market is to reach US$5.7 billion by 2018 - Transparency Market Research

Industry Today

Epigenetics deals with the study of gene expression without altering the gene sequence. The epigenetic change associated with gene expression happens with the modification of the transcription mechanism. The key components that are involved in the regulation of epigenetic transcription are DNA methylation, micro RNA, histone modifications, and non-coding RNA’s.

21 October 2015

3-year-old pharma looks set to fight rectal and eye problems, and then 15 more

Jleg Kouzbit / Marchmont Innovation News

NovaMedica, a young Russian pharma, has been increasingly focused on nanotechnology in its R&D. For example, in the most recent development, this U.S.-Russian JV is about to start a series of clinical trials for its new drug candidate to treat the dangerous inconveniences of hemorrhoids. This is the firm’s inaugural product based on in-house R&D results without tapping into external technologies, the project owners said, claiming that “the drug candidate is built on a unique action mechanism untapped in products currently available in the market.” 

15 October 2015

Diagnostics Special Report: Non-invasion of the body snatchers

DDNEWS

Despite the rapid advances in identifying and understanding the nature of driver mutations and resistance markers in various cancers—information that is going a long way to individualizing patient care—the challenge of fully characterizing a cancer within a single patient remains significant. Even in situations where a solid tumor exists, it is not always possible to obtain a tissue biopsy due to clinical inaccessibility or unacceptable risks to patient safety.

06 October 2015

EyewireTV — Raindrop Near Vision Inlay PMA; MillennialEYE Live

EyewireTV

In this week's EyewireTV, ReVision Optics submits to the FDA the fourth and final module of the company’s premarket approval application for the Raindrop near vision inlay; and Ocular Therapeutix submits a new drug application to the FDA for Dextenza (dexamethasone 0.4 mg) for the treatment of ocular pain following ophthalmic surgery. Also, future and current leaders in ophthalmology discuss the hottest topics from annual MillennialEYE Live meeting in Hollywood. 

06 October 2015

ReVision Optics Files Final Module of FDA Premarket Approval Application for Raindrop Near Vision Inlay

ReVision Optics announced the submission to the FDA of the fourth and final module of the company’s premarket approval (PMA) application for the Raindrop near vision inlay, according to a company news release. The Raindrop is a microscopic hydrogel inlay designed to correct presbyopia, thus reducing or even eliminating the need for reading glasses. The fourth module includes clinical data from more than 300 subjects who have been followed for at least 24 months post-procedure.

29 September 2015

Syndax and Merck Announce First Patients Dosed in Phase 1b/2 Clinical Trial of Entinostat and KEYTRUDA

The FINANCIAL

Syndax Pharmaceuticals, Inc. and Merck, known as MSD outside the United States and Canada, today announced the dosing of the first patients in the Phase 1b/2 clinical trial of Syndax’s entinostat in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in patients with non-small cell lung cancer (NSCLC) or melanoma.

15 September 2015

Tackling presbyopia with an inlay

Vanessa Caceres, Jeffrey Whitman MD / Ophthalmology Times

The Raindrop Near Vision Inlay (ReVision Optics) to treat presbyopia provided good near visual acuity without glasses in a study conducted and presented by Jeffrey Whitman, MD. The inlay, which is still an investigational device in the U.S., is inserted under a LASIK flap. It is a microscopic hydrogel inlay that creates a central steepening of the cornea to give a greater depth of focus, said Dr. Whitman, Key-Whitman Eye Center, Dallas.

11 September 2015

New blood test helps detect cancer early

Gary Robbins / The San Diego Union-Tribune

A blood test that was scarcely heard of two years ago is quickly emerging as an alternative to the often painful practice of using needles or surgery to sample a patient’s tissues for signs of cancer. Scientists from San Diego to Boston said the new “liquid biopsies” can easily detect potentially harmful tumor cells and mutated DNA traveling through the blood stream.

03 September 2015

Tragara Pharmaceuticals $13.06 million Financing. Thomas M Estok Filed Sep 1 SEC Form

Private Financing News

Tragara Pharmaceuticals, Inc., Corporation just had published form D about $13.06 million equity financing. This is a new filing. Tragara Pharmaceuticals was able to fundraise $13.06 million. That is 100.00% of the financing round. The total fundraising amount was $13.06 million. The financing document was filed on 2015-09-01.